Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accounts Payables (2016 - 2025)

vTv Therapeutics' Accounts Payables history spans 12 years, with the latest figure at $6.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 30.44% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 30.44%, while the annual FY2025 figure was $6.6 million, 30.44% up from the prior year.
  • Accounts Payables for Q4 2025 was $6.6 million at vTv Therapeutics, down from $9.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $12.5 million in Q1 2022 and bottomed at $4.2 million in Q1 2025.
  • The 5-year median for Accounts Payables is $7.1 million (2022), against an average of $7.4 million.
  • The largest annual shift saw Accounts Payables surged 316.78% in 2021 before it tumbled 52.0% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $8.0 million in 2021, then dropped by 8.85% to $7.3 million in 2022, then soared by 40.05% to $10.2 million in 2023, then crashed by 50.92% to $5.0 million in 2024, then surged by 30.44% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Accounts Payables are $6.6 million (Q4 2025), $9.8 million (Q3 2025), and $5.2 million (Q2 2025).